In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week:
Those of us with MS know that if something can repair our myelin, the nerve insulator attacked by MS, there’s a good chance some of our MS symptoms could be reversed. So this announcement, written by, certainly lit my radar. Though this trial is limited to patients with a different disease, it’s certainly encouraging that this type of trial is moving ahead.
A cell therapy intended to boost myelin regeneration — Q-Cells by Q Therapeutics — has received a green light from the U.S. Food and Drug Administration to proceed with a clinical trial in patients with transverse myelitis (TM), a disease that, like multiple sclerosis, is characterized by myelin damage.
FDA approval of the company’s Investigational New Drug (IND) application allows researchers to start a Phase 1/2 clinical trial in which nine patients will receive increasing doses of the treatment.
Neither of the statements in this headline should surprise someone who has MS, particularly if that person frequents MS web sites and Facebook pages. As Ocrevus has stirred up a ton of interest among patients and doctors since it was approved by the FDA less than six months ago. But getting insurance to pay for it, or for some other of the newer disease modifying drugs, can be easier said than done.reports,
The market introduction of Ocrevus (ocrelizumab’s) is off to a stellar start, with nearly half of neurologists surveyed by Spherix Global Insights saying they are using the therapy — the first-ever approved for both relapsing and primary progressive multiple sclerosis (MS).
Within six months, 80 percent of neurologists are expected to prescribe Ocrevus, according to a report in the second-quarter edition of RealTime Dynamix: Multiple Sclerosis by Spherix Global Insights.
But insurance is having an increasing impact on treatment decisions, the report also found.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?